Advertisement

Annals of Nuclear Medicine

, Volume 33, Issue 4, pp 295–302 | Cite as

18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma

  • Francesco CiconeEmail author
  • Luciano Carideo
  • Claudia Scaringi
  • Antonietta Arcella
  • Felice Giangaspero
  • Francesco Scopinaro
  • Giuseppe Minniti
Short Communication

Abstract

Objective

The role of amino acid positron emission tomography (PET) in glioma grading and outcome prognostication has not yet been well established. This is particularly true in the context of the new WHO 2016 classification, which introduced a definition of glioma subtypes primarily based on molecular fingerprints. The aim of the present study was to correlate 3,4‑dihydroxy‑6‑[18F]‑fluoro-l‑phenylalanine (F-DOPA) uptake parameters with IDH mutation, 1p/19q status, and survival outcomes in patients with glioma.

Methods

The study population consisted of 33 patients (17 M/16 F, mean age: 46 ± 13 years) who underwent F-DOPA PET/CT for the evaluation of tumor extent before the start of chemo or radiotherapy. The presence of IDH mutation and 1p/19q status was assessed in all the cases. Tumor volume and semiquantitative uptake parameters, namely SUVmax, tumor-to-normal brain ratio and tumor-to-normal striatum ratio, were calculated for each tumor. Imaging-derived parameters were compared between patients stratified according to molecular fingerprints, using parametric or non-parametric tests, where appropriate. The Kaplan–Meier method was used to assess differences of overall survival (OS) and progression-free survival (PFS) between groups. PET parameters were also tested as prognostic factors in univariate Cox survival regression models.

Results

There were 12 IDH-wild-type and 21 IDH-mutant patients. Stratification according to 1p/19q co-deletion resulted in 20 non-co-deleted and 13 co-deleted patients. Median follow-up time from PET/CT exam was 30.5 months (range 3.5–74 months). Semiquantitative uptake parameters did correlate neither with IDH mutation nor with 1p/19q status. Uptake was similar in low-grade and high-grade tumors, respectively. In addition, F-DOPA uptake parameters, macroscopic tumor volume, or tumor grade did not stratify OS, while a correlation between SUVmax and PFS was shown in the subgroup of astrocytomas. On the other hand, IDH mutation status and presence of 1p/19q co-deletion had a significant impact on survival outcomes. The prognostic value of IDH mutation status was also confirmed in the subgroup of patients with astrocytic tumors.

Conclusions

F-DOPA uptake parameters do not correlate with tumor molecular and histological characteristics. The predictive value of PET-derived parameters on outcomes of survival is limited.

Keywords

Amino acid PET DOPA Glioma IDH mutation 1p/19q co-deletion WHO 2016 

Notes

Funding

None.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.CrossRefGoogle Scholar
  2. 2.
    Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372:2499–508.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response assessment in neuro-oncology working group and european association for neuro-oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18:1199–208.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Filss CP, Cicone F, Shah NJ, Galldiks N, Langen KJ. Amino acid PET and MR perfusion imaging in brain tumors. Clin Transl Imaging. 2017;5:209–23.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Langen KJ, Galldiks N, Hattingen E, Shah NJ. Advances in neuro-oncology imaging. Nat Rev Neurol. 2017;13:279–89.CrossRefPubMedGoogle Scholar
  6. 6.
    Bette S, Gempt J, Delbridge C, Kirschke JS, Schlegel J, Foerster S, et al. Prognostic value of O-(2-[18F]-Fluoroethyl)-l-tyrosine-positron emission tomography imaging for histopathologic characteristics and progression-free survival in patients with low-grade glioma. World Neurosurg. 2016;89:230–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Iwadate Y, Shinozaki N, Matsutani T, Uchino Y, Saeki N. Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography. J Neurol Neurosurg Psychiatry. 2016;87:1016–21.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging. 2017;44:1155–64.CrossRefPubMedGoogle Scholar
  9. 9.
    Verger A, Metellus P, Sala Q, Colin C, Bialecki E, Taieb D, et al. IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas. Eur J Nucl Med Mol Imaging. 2017;44:1306–11.CrossRefPubMedGoogle Scholar
  10. 10.
    Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR, et al. Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging. 2018;45:443–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Blanc-Durand P, Van Der Gucht A, Verger A, Langen KJ, Dunet V, Bloch J, et al. Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: a significant association with IDH1 mutation status and survival in patients with gliomas. PLoS One. 2018;13:e0199379.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Minniti G, Arcella A, Scaringi C, Lanzetta G, Di Stefano D, Scarpino S, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers. J Neurooncol. 2014;116:275–82.CrossRefPubMedGoogle Scholar
  13. 13.
    Carideo L, Minniti G, Mamede M, Scaringi C, Russo I, Scopinaro F, et al. 18F-DOPA uptake parameters in glioma: effects of patients’ characteristics and prior treatment history. Br J Radiol. 2018;91:20170847.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Suchorska B, Albert NL, Bauer EK, Tonn JC, Galldiks N. The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. Q J Nucl Med Mol Imaging. 2018;62:267–71.CrossRefPubMedGoogle Scholar
  15. 15.
    Isal S, Gauchotte G, Rech F, Blonski M, Planel S, Chawki MB, et al. A high (18)F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II–III gliomas. Br J Radiol. 2018;91:20170803.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Shinozaki N, Uchino Y, Yoshikawa K, Matsutani T, Hasegawa A, Saeki N, et al. Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. J Neurosurg. 2011;114:1640–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro Oncol. 2012;14:1473–80.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013;15:1058–67.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Manabe O, Hattori N, Yamaguchi S, Hirata K, Kobayashi K, Terasaka S, et al. Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging. Eur J Nucl Med Mol Imaging. 2015;42:896–904.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Department of Nuclear Medicine and Molecular ImagingLausanne University HospitalLausanneSwitzerland
  2. 2.Nuclear Medicine, Department of Surgical and Medical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Sant’Andrea HospitalSapienza University of RomeRomeItaly
  3. 3.Department of Surgical and Medical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Radiotherapy, Sant’Andrea HospitalSapienza University of RomeRomeItaly
  4. 4.Radiation Oncology Unit, UPMC Hillman Cancer CenterSan Pietro Hospital FBFRomeItaly
  5. 5.IRCCS NeuromedPozzilliItaly
  6. 6.Department of Radiological, Oncological and Anatomo Pathological SciencesSapienza University of RomeRomeItaly

Personalised recommendations